GART
Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase
As of the edition of 20 October 2026, GART (trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase, UniProt P22102) has 2 drugs tested at it and 10 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P22102
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 40
- Disease areas
- Cancer; Lungs and airways; Digestive system; Urinary and reproductive; Nervous system; Pregnancy and women's health; Skin and connective tissue; Hormones
- Registered trials of its drugs
- 955
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Pemetrexed | Marketed | Phase 4 | none listed |
| Pelitrexol | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 8 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
| Nippon Kayaku | Route B |
The other 8 companies at GART
In the product10 companies in all; 8 are not named here, and no score is.
See the 10 companies at GART, ranked, with the facts behind eachRequest access. Nothing is shown until you do.